Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 56 for “"biosimilar"”.

  1. Biosimilar uptake in the United States: Examining state-level longitudinal trends in biosimilar filgrastim use and their association with biosimilar substitution policies

    … Instead, a similar agent, known as a biosimilar is developed, which demonstrates equivalent effectiveness and safety as the reference brand3. Recognizing the need for increased affordability of promising biologic therapies, many countries have established approval pathways for …

    washington Repository record for Biosimilar uptake in the United States: Examining state-level longitudinal trends in biosimilar filgrastim use and their association with biosimilar substitution policies (opens in a new tab)

  2. Eficacia y seguridad del biosimilar ABP 501 (Adalimumab) comparado con biosimilar CT-P13 (Infliximab) en pacientes adultos con artritis reumatoide. Revisión sistemática

    … evidence of comparative studies between biosimilars that demonstrate safety and efficacy, this being relevant for clinicians and insurers to feel supported at the time of acquiring and prescribing this type of molecules. In Colombia, since it is a disease with late diagnosis and that …

    rosario Repository record for Eficacia y seguridad del biosimilar ABP 501 (Adalimumab) comparado con biosimilar CT-P13 (Infliximab) en pacientes adultos con artritis reumatoide. Revisión sistemática (opens in a new tab)

  3. Sample Size Determination for a Three-arm Biosimilar Trial

    The equivalence assessment usually consists of three tests and is often conducted through a three-arm clinical trial. The first two tests are to demonstrate the superiority of the test treatment and the reference treatment to placebo, and they are followed by the equivalence test between the test …

    temple Repository record for Sample Size Determination for a Three-arm Biosimilar Trial (opens in a new tab)

  4. How a biosimilar switching policy impacted healthcare resource utilization and cost in British Columbia

    The uptake of biosimilars has been slower than hoped in many jurisdictions across the globe. A concern has been raised that switch from originator to biosimilar would be associated with increased health care resource utilization (HCRU) such as increased physician visits and hospitalizations. …

    ubc Repository record for How a biosimilar switching policy impacted healthcare resource utilization and cost in British Columbia (opens in a new tab) Download PDF for How a biosimilar switching policy impacted healthcare resource utilization and cost in British Columbia (opens in a new tab)

  5. Comparative Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilar Comparability Analysis

    … soon. Consequently, the interest of developing biosimilar products is growing. A biosimilar product is developed if there are no clinically meaningful differences in terms of safety, efficacy, and purity after evaluating side-by-side with the originator. Biosimilar products are anticipated to be …

    ku Repository record for Comparative Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilar Comparability Analysis (opens in a new tab)

  6. Comparative Effect of Herceptin and Its Biosimilar: Transcriptomic and Proteomic Insights from HER2-Positive Cancer Cell Lines

    … in 2019, opening the door for the development of biosimilars. Biosimilars are copies of the originator product that must demonstrate biosimilarity for regulatory approval. This is a very difficult task. Antibodies are large molecules that undergo extensive post-translational modifications (PTMs), …

    waterloo Repository record for Comparative Effect of Herceptin and Its Biosimilar: Transcriptomic and Proteomic Insights from HER2-Positive Cancer Cell Lines (opens in a new tab)

  7. A requirement analysis of software tools for biosimilar development process : enhancing the functionality of Alvotech’s development blueprint

    … has grown correspondingly. The development of biosimilars needs efficient planning and scheduling for their success. Alvotech, a biopharmaceutical company that specializes in creating biosimilars, utilizes a structured process framework for their development process called the ‘Alvotech …

    reykjavik Repository record for A requirement analysis of software tools for biosimilar development process : enhancing the functionality of Alvotech’s development blueprint (opens in a new tab)

  8. Biosimilars in the United States: Market Dynamics and Patient Out-of-Pocket Costs

    BackgroundThe United States biosimilars market is growing rapidly and has led to significant savings for the health care system and payers. However, market complexities, barriers to entry, and fewer biosimilars in the pipeline than expected has led to concerns about the long-term sustainability of …

    washington Repository record for Biosimilars in the United States: Market Dynamics and Patient Out-of-Pocket Costs (opens in a new tab)

  9. Valoración de la eficacia de Infliximab biosimilar (CT-P13, remsima®) frente al Infliiximab original (Remicade®) en pacientes con enfermedad inflamatoria intestinal.

    … patentes, se ha llevado a cabo el desarrollo de biosimilares de estos fármacos, con el objetivo de proporcionar importantes ahorros de costes y una mayor accesibilidad al tratamiento. En 2013, la Agencia de Medicamentos Europea (EMA) aprobó el primer biosimilar del Infliximab (CT-P13) con las …

    sevilla Repository record for Valoración de la eficacia de Infliximab biosimilar (CT-P13, remsima®) frente al Infliiximab original (Remicade®) en pacientes con enfermedad inflamatoria intestinal. (opens in a new tab)

  10. Association between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products

    Importance. Targeted policy efforts regarding biosimilars need to be informed by empirical evidence as to their cost containment potential. The 2015 launch of filgrastim-sndz, the first U.S. biosimilar, provides a natural experiment in which to evaluate the biosimilar experience in the United …

    jhu Repository record for Association between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products (opens in a new tab)

  11. Healthcare Professionals' Perceptions of Generic and Biosimilar Medicines in Abu Dhabi : A Mixed-Methods Study of Adoption Barriers and Facilitators

    Introduction The adoption of generic and biosimilar medicines is important for healthcare system sustainability and equitable access to effective treatment. Despite strong regulatory frameworks and growing international evidence supporting therapeutic equivalence, uptake remains suboptimal. This …

    lancaster Download PDF for Healthcare Professionals' Perceptions of Generic and Biosimilar Medicines in Abu Dhabi : A Mixed-Methods Study of Adoption Barriers and Facilitators (opens in a new tab)

  12. Evaluation of Bottom-Up and Middle-Up Liquid Chromatography Mass Spectrometry Methods for Forced Degradation Studies applied in Biosimilar Development

    … The reference medicinal products (RMPs) and biosimilar candidates of the two mAbs bevacizumab and infliximab were subjected to forced oxidation by H2O2 to investigate their susceptibility to oxidation. In a first step, middle-up analysis was established. PTM analysis of unstressed samples, …

    fu-berlin Repository record for Evaluation of Bottom-Up and Middle-Up Liquid Chromatography Mass Spectrometry Methods for Forced Degradation Studies applied in Biosimilar Development (opens in a new tab)

  13. An Analysis of Trends of Generic Drugs and Biologic Prices in the U.S.

    … for the US healthcare system. Generic and biosimilar market competition reduces drug and biologic prices, results in substantial savings, and improves patient access and outcomes. As the costs of healthcare and prescription drugs continue to rise, the discussion about drug prices has taken …

    chapman Repository record for An Analysis of Trends of Generic Drugs and Biologic Prices in the U.S. (opens in a new tab)

  14. Delay-and-pay: prolonging pharmaceutical patent protection without paying the ‘price’

    … for as long as possible by delaying generic/biosimilar market entry – and that they have a significant incentive to do so. This strategy is based on the notion that it is significantly more profitable for patentees to delay generic/biosimilar market entry by way of a patent infringement claim …

    oxford Restricted access

  15. Biosimilars: A New Look on Process Innovation and the Impact of Competitive Dynamics

    … segment of the cost, governments have created biosimilar regulatory pathways in attempt to lower the costs of biologics. Biosimilars may be viewed as a “pure” or distinct type of process innovation completely separate from product innovation due to the Regulatory requirements and this novel …

    temple Repository record for Biosimilars: A New Look on Process Innovation and the Impact of Competitive Dynamics (opens in a new tab)

  16. TGF-β2 in human milk research: Exploration of a new field methodology and new findings of biosimilar TGF-β2 in non-human milk

    … and lastly, to explore the ramifications of biosimilar TGF-β2 across multiple milks on human health, growth, and immunity through the review of laboratory findings and previous literature. Rational: Little anthropological research has been done on TGF-β2 in human milk. Anthropology as a …

    usf Repository record for TGF-β2 in human milk research: Exploration of a new field methodology and new findings of biosimilar TGF-β2 in non-human milk (opens in a new tab)

  17. Beurteilung von orthogonalen analytischen Methoden zur physikochemischen Charakterisierung von monoklonalen Antikörperproben in einer Biosimilarvergleichsstudie mit forcierter Degradation

    Die Firma ProBioGen hat ein Bevacizumab Biosimilar hergestellt, das im Rahmen einer vergleichenden Qualitätsstudie mit dem Marktprodukt untersucht werden sollte. Dazu wurden für diese Arbeit analytische Methoden etabliert, um verschiedene Qualitätsmerkmale der Bevacizumab-Proben zu erfassen und …

    fu-berlin Repository record for Beurteilung von orthogonalen analytischen Methoden zur physikochemischen Charakterisierung von monoklonalen Antikörperproben in einer Biosimilarvergleichsstudie mit forcierter Degradation (opens in a new tab)

Page 1 of 3